The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The first study to be retracted, published last month (May 22) in The Lancet, had found harmful effects associated with the antimalarial drug, hydroxychloroquine, but quickly drew fire after ...

Cases of lung cancer among those who never smoked is on the rise and air pollution could be contributing to the increase, ...

Spencer, a new commission convened by the medical journal The Lancet will recommend how to build more resilient communities ...

Antibiotic overuse is a key driver in the rise of antimicrobial resistance (AMR), a major global health crisis. Researchers ...